{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Symptom+Clusters&page=47", "query": { "condition": "Symptom Clusters", "page": 47 }, "page_size": 10 }, "pagination": { "page": 47, "page_size": 10, "total_count": 16818, "total_pages": 1682, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Symptom+Clusters&page=48&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Symptom+Clusters&page=46&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T23:38:49.543Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01095796", "title": "Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "Stribild", "type": "DRUG" }, { "name": "Atripla", "type": "DRUG" }, { "name": "Stribild Placebo", "type": "DRUG" }, { "name": "Atripla Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 707, "start_date": "2010-03", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2015-11-11", "last_synced_at": "2026-10-27T23:38:49.543Z", "location_count": 97, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 63 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Hayward", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01095796" }, { "nct_id": "NCT05364762", "title": "Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndrome", "Myeloproliferative Neoplasm", "Primary Myelofibrosis", "Secondary Myelofibrosis" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Itacitinib", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "80 Years", "sex": "ALL", "summary": "Up to 80 Years" }, "enrollment_count": 20, "start_date": "2022-12-29", "completion_date": "2027-03-25", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-27T23:38:49.543Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05364762" }, { "nct_id": "NCT03137446", "title": "Restrictive Intravenous Fluids Trial in Sepsis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Septic Shock", "Severe Sepsis" ], "interventions": [ { "name": "Intravenous Fluid Cap", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Rhode Island Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2017-04-20", "completion_date": "2018-03-30", "has_results": false, "last_update_posted_date": "2018-08-31", "last_synced_at": "2026-10-27T23:38:49.543Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT03137446" }, { "nct_id": "NCT00068523", "title": "Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "UV light therapy", "type": "PROCEDURE" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 10, "start_date": "2003-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-07-27", "last_synced_at": "2026-10-27T23:38:49.543Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00068523" }, { "nct_id": "NCT05133180", "title": "Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dry Eye" ], "interventions": [ { "name": "Oxervate", "type": "DRUG" }, { "name": "Vehicle", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Dompé Farmaceutici S.p.A", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2022-01-19", "completion_date": "2022-12-19", "has_results": true, "last_update_posted_date": "2024-06-07", "last_synced_at": "2026-10-27T23:38:49.543Z", "location_count": 7, "location_summary": "Glendale, California • Newport Beach, California • Baltimore, Maryland + 4 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05133180" }, { "nct_id": "NCT01818596", "title": "Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2013-03-27", "completion_date": "2018-07-18", "has_results": true, "last_update_posted_date": "2020-03-02", "last_synced_at": "2026-10-27T23:38:49.543Z", "location_count": 51, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Hayward", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01818596" }, { "nct_id": "NCT06501196", "title": "A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Leukemia, Myeloid", "Leukemia, Myeloid, Acute", "Preleukemia", "Myelodysplastic Syndromes", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "BH-30236", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BlossomHill Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2024-06-19", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-09-24", "last_synced_at": "2026-10-27T23:38:49.543Z", "location_count": 13, "location_summary": "Duarte, California • Los Angeles, California • Palo Alto, California + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06501196" }, { "nct_id": "NCT00065403", "title": "Acupuncture for Irritable Bowel Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Irritable Bowel Syndrome" ], "interventions": [ { "name": "Acupuncture", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "National Center for Complementary and Integrative Health (NCCIH)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 260, "start_date": "2004-02", "completion_date": "2005-09", "has_results": false, "last_update_posted_date": "2006-08-18", "last_synced_at": "2026-10-27T23:38:49.543Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00065403" }, { "nct_id": "NCT01440569", "title": "Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "COBI", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "NRTIs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2011-09", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2016-12-14", "last_synced_at": "2026-10-27T23:38:49.543Z", "location_count": 48, "location_summary": "Phoenix, Arizona • Long Beach, California • Los Angeles, California + 39 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01440569" }, { "nct_id": "NCT03921554", "title": "JAK Inhibitor Treatment in AGS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Aicardi Goutieres Syndrome" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adeline Vanderver, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": null, "sex": "ALL", "summary": "1 Month and older" }, "enrollment_count": 54, "start_date": "2019-06-03", "completion_date": "2024-03-25", "has_results": true, "last_update_posted_date": "2025-12-30", "last_synced_at": "2026-10-27T23:38:49.543Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03921554" } ] }